drugset

drugset / Trial / NCT04226989

A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

NCT04226989 ↗

Phase 0 Unknown 72 enrolled He Huang Nanjing Bioheng Biotech Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

Timeline

Start: 2020-02-05
Primary completion: 2022-02-05
Completion: 2024-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CT-RD06	Cell therapy	—	Intravenous

Indications